Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS)‘s stock had its “ourperform” rating reaffirmed by research analysts at William Blair in a report issued on Friday.

Other research analysts also recently issued reports about the stock. Noble Financial reissued a “buy” rating on shares of Adamas Pharmaceuticals in a research report on Wednesday, August 9th. Cowen and Company set a $45.00 target price on shares of Adamas Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, August 9th. Mizuho reaffirmed a “buy” rating and issued a $26.00 target price on shares of Adamas Pharmaceuticals in a report on Tuesday, June 6th. Zacks Investment Research raised shares of Adamas Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, July 11th. Finally, JMP Securities reaffirmed an “outperform” rating and issued a $33.00 target price (up previously from $29.00) on shares of Adamas Pharmaceuticals in a report on Friday. Two analysts have rated the stock with a sell rating and four have issued a buy rating to the company. The company has an average rating of “Hold” and an average target price of $32.50.

Adamas Pharmaceuticals (NASDAQ ADMS) opened at 19.93 on Friday. The company’s market capitalization is $448.70 million. Adamas Pharmaceuticals has a one year low of $12.10 and a one year high of $21.44. The company has a 50-day moving average price of $16.54 and a 200-day moving average price of $16.78.

Adamas Pharmaceuticals (NASDAQ:ADMS) last issued its quarterly earnings data on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.93) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.81) by $0.12. Adamas Pharmaceuticals had a negative return on equity of 52.91% and a negative net margin of 10,499.65%. The business had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.03 million. During the same period in the previous year, the business posted ($0.78) earnings per share. The company’s revenue for the quarter was down 90.9% on a year-over-year basis. Analysts expect that Adamas Pharmaceuticals will post ($3.80) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “William Blair Reiterates “Ourperform” Rating for Adamas Pharmaceuticals, Inc. (ADMS)” was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece of content on another publication, it was illegally stolen and republished in violation of U.S. & international copyright & trademark law. The legal version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/08/27/william-blair-reiterates-ourperform-rating-for-adamas-pharmaceuticals-inc-adms.html.

In other Adamas Pharmaceuticals news, major shareholder Great Point Partners Llc sold 350,000 shares of Adamas Pharmaceuticals stock in a transaction dated Monday, June 19th. The shares were sold at an average price of $17.05, for a total transaction of $5,967,500.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In the last 90 days, insiders have sold 731,041 shares of company stock valued at $12,476,149. 29.00% of the stock is currently owned by company insiders.

Several institutional investors have recently bought and sold shares of the stock. Tower Research Capital LLC TRC purchased a new position in Adamas Pharmaceuticals during the second quarter worth $109,000. State Street Corp raised its position in Adamas Pharmaceuticals by 9.1% in the second quarter. State Street Corp now owns 285,359 shares of the specialty pharmaceutical company’s stock worth $4,990,000 after buying an additional 23,708 shares in the last quarter. Bamco Inc. NY raised its position in Adamas Pharmaceuticals by 45.5% in the second quarter. Bamco Inc. NY now owns 103,200 shares of the specialty pharmaceutical company’s stock worth $1,805,000 after buying an additional 32,272 shares in the last quarter. Dimensional Fund Advisors LP raised its position in Adamas Pharmaceuticals by 11.9% in the second quarter. Dimensional Fund Advisors LP now owns 140,481 shares of the specialty pharmaceutical company’s stock worth $2,457,000 after buying an additional 14,987 shares in the last quarter. Finally, Virtu KCG Holdings LLC purchased a new position in Adamas Pharmaceuticals during the second quarter worth $184,000. 70.86% of the stock is owned by institutional investors and hedge funds.

Adamas Pharmaceuticals Company Profile

Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.

Receive News & Stock Ratings for Adamas Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.